What is William Blair’s Estimate for EW FY2025 Earnings?

Edwards Lifesciences Corporation (NYSE:EW) – Equities research analysts at William Blair raised their FY2025 EPS estimates for shares of Edwards Lifesciences in a research note issued to investors on Friday, October 31st. William Blair analyst B. Vazquez now expects that the medical research company will post earnings of $2.58 per share for the year, up from their previous estimate of $2.48. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. William Blair also issued estimates for Edwards Lifesciences’ Q4 2025 earnings at $0.60 EPS, Q1 2026 earnings at $0.67 EPS, Q2 2026 earnings at $0.72 EPS, Q3 2026 earnings at $0.72 EPS, Q4 2026 earnings at $0.69 EPS, FY2026 earnings at $2.80 EPS, Q1 2027 earnings at $0.73 EPS, Q2 2027 earnings at $0.80 EPS, Q3 2027 earnings at $0.79 EPS and FY2027 earnings at $3.09 EPS.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the business posted $0.67 earnings per share. The business’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS.

A number of other equities research analysts also recently weighed in on EW. National Bankshares set a $92.00 target price on Edwards Lifesciences in a report on Friday. Sanford C. Bernstein restated a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday. Evercore ISI increased their target price on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. The Goldman Sachs Group set a $104.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday. Finally, Morgan Stanley increased their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.39.

Edwards Lifesciences Trading Up 1.3%

Shares of NYSE:EW opened at $84.13 on Monday. Edwards Lifesciences has a 12 month low of $64.89 and a 12 month high of $87.09. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The company’s fifty day simple moving average is $77.68 and its 200 day simple moving average is $77.14. The firm has a market cap of $49.39 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 3.97 and a beta of 1.05.

Institutional Investors Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EW. Parkside Financial Bank & Trust grew its holdings in shares of Edwards Lifesciences by 9.8% in the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 130 shares in the last quarter. Prosperity Consulting Group LLC grew its holdings in shares of Edwards Lifesciences by 3.2% in the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock valued at $337,000 after purchasing an additional 132 shares in the last quarter. Howard Capital Management Inc. boosted its stake in Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after buying an additional 132 shares during the period. NewSquare Capital LLC boosted its stake in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after buying an additional 134 shares during the period. Finally, Empirical Finance LLC boosted its stake in Edwards Lifesciences by 0.6% during the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after buying an additional 134 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.